Trial Profile
Phase II Study of Neoadjuvant IMC-A12 Combined With Androgen Deprivation Prior to Prostatectomy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Cixutumumab (Primary) ; Bicalutamide; Goserelin
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- 25 Nov 2011 Actual end date Nov 2011 added as reported by ClinicalTrials.gov.
- 25 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.